Early buyers will receive 10% customization on this report.
Major Market Players:
The key players in the market are Enterome Bioscience (France), Yakult Honsha Co., Ltd. (Japan), E. I. Du Pont de Nemours and Company (U.S.), Metabiomics Corporation (U.S.), ViThera Pharmaceuticals (U.S.), Second Genome, Inc. (U.S.), microbiome Therapeutics LLC (U.S.), Vedanta BioSciences, Inc. (U.S.), Osel, Inc. (U.S.), and Merck & Co, Inc. (U.S.)
Europe is expected to account for the largest share of the global human microbiome market in 2022. The large share of this region can be attributed to its significant presence in the probiotics and prebiotics fields and the acceptance of these products by its population.
A number of factors such as the rising incidence of cardiovascular disease, increasing awareness about the need for diagnostic and preventive care, and technological advancement are driving the growth of this market. In developed regions like North America, the human microbiome market, in terms of value, is expected to be smaller as compared to Europe, owing to the slower acceptance of microbiome products in a number of countries in this region.
The human microbiome market is an emerging market with abundant opportunities. The market is expected to flourish within five to seven years owing to a number of products currently in the clinical trial phase. The market potential is quite large, considering the structure of the market.
The factors driving this market include rising aging population, increasing incidence of lifestyle diseases, gradual demand for efficient and safe medication with no side effects, and treatment of diseases having a limited success rate. The factors restraining this market include lack of comprehensive research to assist in market pull, lack of awareness among the population regarding the efficient usage and effect of prebiotics and probiotics, and impending government regulations on probiotics and prebiotics.
About MarketsandMarkets:
MarketsandMarkets provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets. For more information, please visit www.marketsandmarkets.com
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
